Clinical Trials Sponsored by Loxbridge Research LLP

Total 1811 results

Janssen Research & Development, LLC

Terminated

A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (LYRA)

Hidradenitis Suppurativa

United States, Germany, Canada, Japan, Netherlands, Spain, Australia, Poland
Janssen Research & Development, LLC

Completed

Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity

Insomnia

Germany, United States, Netherlands
Janssen Research & Development, LLC

Terminated

A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant

Depressive Disorder, Major

United States, United Kingdom
Janssen Research & Development, LLC

Completed

A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants

Healthy

Germany
Janssen Research & Development, LLC

Completed

A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

China
Janssen Research & Development, LLC

Active, not recruiting

A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection (PROGRESS)

Crohn's Disease

United States, Poland
Janssen Research & Development, LLC

Completed

A Study of Paliperidone Palmitate 6-Month Formulation

Schizophrenia

United States, Korea, Republic of, Hong Kong, Taiwan, Malaysia, Czechia, Poland, Brazil, India, Spain, Argentina, Bulgaria, Turkey, Russian Federation, Ukraine, Hungary, South Africa, Mexico, Australia, France, Italy
Janssen Research & Development, LLC

Approved for marketing

Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

Metastatic Castration-resistant Prostate Cancer

Brazil, Austria, Estonia, Israel, Mexico
Janssen Research & Development, LLC

Completed

A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children

Human Immunodeficiency Virus (HIV)

United States, Spain, South Africa
Janssen Research & Development, LLC

Completed

A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge

Healthy

Belgium
Janssen Research & Development, LLC

Approved for marketing

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Brazil, Germany, Italy, Netherlands, Romania, Switzerland, United Kingdom
Janssen Research & Development, LLC

Completed

A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795

Fatty Liver Disease

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, Spain, Germany
Janssen Research & Development, LLC

Completed

A Study of Guselkumab in Participants With Familial Adenomatous Polyposis

Adenomatous Polyposis Coli

United States, Germany, France, Israel, Netherlands, Poland, Puerto Rico, Spain, Sweden
Janssen Research & Development, LLC

Terminated

Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

Germany
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Depressive Disorder, Major

United States, Bulgaria, Ukraine, Russian Federation, Germany, Finland, Japan, France
Janssen Research & Development, LLC

Terminated

A Single and Multiple Ascending Dose Study of JNJ-64457744

Healthy | Hepatitis B, Chronic

New Zealand
Janssen Research & Development, LLC

Completed

A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Janssen Research & Development, LLC

Completed

A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants

Healthy

China
Janssen Research & Development, LLC

Completed

A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis

Adenomatous Polyposis Coli

United States, Germany, Korea, Republic of, France, Netherlands, Spain, Puerto Rico
Janssen Research & Development, LLC

Completed

A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants

Healthy

United States
Janssen Research & Development, LLC

Terminated

A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Dermatitis, Atopic

United States, Argentina
Janssen Research & Development, LLC

Completed

A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis

Colitis, Ulcerative

United States, France, Belgium, Israel, Canada, Netherlands, Austria, Poland, Denmark, Germany
Janssen Research & Development, LLC

Completed

A Study in a Human Laboratory Model of Smoking Behavior

Smoking

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder

Depressive Disorder, Major

Belgium, United Kingdom, Germany, United States, Netherlands
Janssen Research & Development, LLC

Completed

A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors

Neoplasms

Spain, Israel
Janssen Research & Development, LLC

Completed

A Study of JNJ-42847922 (Seltorexant) in Healthy Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Terminated

A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (GENESIS)

Dermatitis, Atopic

United States, Germany, Canada, Poland, Japan
Janssen Research & Development, LLC

Completed

Study to Estimate How Common it is to Have Genetic Variants Associated With NAFLD

Healthy

United States
Urological Research Network, LLC

Active, not recruiting

Office Based Transperineal Laser Ablation for Benign Prostatic Hyperplasia HYPERPLASIA

Prostatic Hyperplasia | Male Urogenital Diseases | Genital Diseases, Male | Prostatic Disease

United States
Janssen Research & Development, LLC

Completed

A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Belgium, Israel, Spain
Janssen Research & Development, LLC

Approved for marketing

Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC

Completed

An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress

Depressive Disorder | Anxiety

Ukraine, United Kingdom, Spain, United States, Russian Federation, Moldova, Republic of
Janssen Research & Development, LLC

Completed

A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors

Neoplasms

United States, Canada
Janssen Research & Development, LLC

Completed

A Study of Macitentan/Tadalafil Combination Administered a Fixed-dose Combination Formulation Compared to the Reference Free Combination of Macitentan and Tadalafil

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate Agents

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study to Investigate the Effect of JNJ-67953964 on Gastric Mucosal Integrity in Healthy Male and Female Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea

Sleep Apnea, Obstructive

United States
Janssen Research & Development, LLC

Completed

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Metastatic Breast Cancer | Metastatic Castration-resistant Prostate Cancer

United States, Belgium, Spain, Germany, Sweden, Australia, United Kingdom
GU Research Network, LLC

Withdrawn

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

United States
Janssen Research & Development, LLC

No longer available

Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis

Adenomatous Polyposis Coli
Janssen Research & Development, LLC

Completed

A Study for Schizophrenia Relapse Prediction

Schizophrenia

India
Janssen Research & Development, LLC

Terminated

A Study of JNJ-66525433 in Healthy Participants and Participants With Ulcerative Colitis

Healthy | Colitis, Ulcerative

Germany
Janssen Research & Development, LLC

Completed

A Study to Compare Two Different Subcutaneously-administered JNJ-64304500 Formulations in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Terminated

A Study of Itraconazole in the Management of Superficial Fungal Infections in India

Mycoses

India
Janssen Research & Development, LLC

Withdrawn

A Study of JNJ-56136379 in Healthy Participants

Healthy
Janssen Research & Development, LLC

Completed

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 2

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 1 (PLATFORM)

Healthy

Belgium

3

Subscribe